The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Abstract
The AKT2 gene is one of the human homologues of v‐akt, the transduced oncogene of the AKT8 virus, which induces lymphomas in mice. In previous studies, AKT2, which codes for a serine‐threonine protein kinase, was shown to be amplified and overexpressed in some human ovarian carcinoma cell lines and amplified in primary tumors of the ovary. To confirm and extend these findings, we conducted a large‐scale, multicenter study of AKT2 alterations in ovarian and breast cancer. Southern‐blot analysis demonstrated AKT2 amplification in 16 of 132 (12.1%) ovarian carcinomas and in 3 of 106 (2.8%) breast carcinomas. No AKT2 alteration was detected in 24 benign or borderline tumors. Northern‐blot analysis revealed overexpression of AKT2 in 3 of 25 fresh ovarian carcinomas which were negative for AKT2 amplification. The difference in the incidence of AKT2 alterations in ovarian and breast cancer suggests a specific role for this gene in ovarian oncogenesis. No significant association was found between AKT2 amplification and amplification of the proto‐oncogenes MYC and ERBB2, suggesting that amplification of AKT2 defines an independent subset of breast and ovarian cancers. Ovarian cancer patients with AKT2 alterations appear to have a poor prognosis. Amplification of AKT2 was especially frequent in undifferentiated tumors (4 of 8, p = 0.019), suggesting that AKT2 alterations may be associated with tumor aggressiveness. © 1995 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Cited by
Items 101–125 of 125
Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22862 · Cited by 316
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
Dillon, R. L., White, D. E., & Muller, W. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210202 · Cited by 311
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
Aoki, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011528498 · Cited by 303
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
Apoptosome dysfunction in human cancer
Hajra, K. M., & Liu, J. R. (2004) · Apoptosis · doi:10.1023/b:appt.0000045786.98031.1d · Cited by 291
Targeting AKT for cancer therapy
Shariati, M., & Meric-Bernstam, F. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1676726 · Cited by 290
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287
Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival
Gansler, T. S., Hardman, W., Hunt, D. A., Schaffel, S., & Hennigar, R. A. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90177-5 · Cited by 287
Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling
Kops, G. J. P. L., & Burgering, B. M. T. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900050 · Cited by 283
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase
Zhao, J. J., Gjoerup, O. V., Subramanian, R. R., Cheng, Y., Chen, W., Roberts, T. M., & Hahn, W. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00088-6 · Cited by 279
WALKER, K. S., DEAK, M., PATERSON, A., HUDSON, K., COHEN, P., & ALESSI, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3310299 · Cited by 278
Dahia, P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.185 · Cited by 274
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Uddin, S., Hussain, A. R., Siraj, A. K., Manogaran, P. S., Al-Jomah, N. A., Moorji, A., Atizado, V., Al-Dayel, F., Belgaumi, A., El-Solh, H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016907 · Cited by 262
Future of Personalized Medicine in Oncology: A Systems Biology Approach
Gonzalez-Angulo, A. M., Hennessy, B. T. J., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0777 · Cited by 261
PDK1, one of the missing links in insulin signal transduction?1
Cohen, P., Alessi, D. R., & Cross, D. A. E. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00490-0 · Cited by 246
Marte, B. M., Rodriguez-Viciana, P., Wennström, S., Warne, P. H., & Downward, J. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00028-5 · Cited by 223
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Cohen, P. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0399 · Cited by 158
Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102
Activated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells
Xia, S., Zhao, Y., Yu, S., & Zhang, M. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0707 · Cited by 78
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis
Li, X.-H., Chen, X.-J., Ou, W.-B., Zhang, Q., Lv, Z.-R., Zhan, Y., Ma, L., Huang, T., Yan, Y.-B., & Zhou, H.-M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.003 · Cited by 74
“Activation of Akt is frequently reported n cancer cells, and it has been shown to be activated in numerous uman tumors (Bellacosa et al., 1995; Staal, 1987).”
BackgroundBuchanan, P. C., Boylan, K. L. M., Walcheck, B., Heinze, R., Geller, M. A., Argenta, P. A., & Skubitz, A. P. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746859 · Cited by 73
Metadata
- Authors
- Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Panici, P. B., Mancuso, S., Neri, G., & Testa, J. R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1995-08-22
- Volume
- 64
- Issue
- 4
- Pages
- 280-285
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2059221693
- Cited by
- 837
- References
- 25
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.